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Here, we present the characterisation of the so-far-unstudied NUDIX hydrolase family
member NUDT22. We previously identified the unique hydrolase activity of NUDT22
towards UDP-glucose from a family-wide biochemical substrate screen. UDP-glucose
hydrolysis was found to result in the production of uridine monophosphate (UMP) and
glucose 1-phosphate (G-1-P). We furthermore solved the first crystal structure of NUDT22
in complex with its substrate UDP-glucose [1]. Our mechanistic studies revealed increased
replication stress in NUDT22-deficient cells that could be rescued by nucleoside supple-
mentation. We therefore propose the discovery of a novel NUDT22-mediated pyrimidine
salvage pathway. Increased replication rates resulting in replication stress is a hallmark of
cancer cells, and NUDT22 gene expression alterations are present in several cancer tissues,
which makes NUDT22 an interesting new target for the development of small molecule
inhibitors for uses in cancer. We employed our NUDT22 crystal structure to perform an in
silico docking screen on available small molecule libraries to identify starting points for the
development of first-in-class NUDT22 inhibitors. Chemically optimised NUDT22 inhibitors
are currently being validated in biochemical assays and cellular target engagement assays,
and their cellular activity is being assessed in vitro.
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